---
$id: https://graph.org.ai/products/commodity/51202803
$type: Product
source: UNSPSC
code: "51202803"
title: "Sirolimus"
class: "51202800"
classTitle: "Immunosupressant macrolides"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Sirolimus

**UNSPSC Code**: 51202803
**Class**: [Immunosupressant macrolides](Immunosupressant macrolides.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a bcar2 gene, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W36ZG6FT64. European Medicines Agency schedules Rapamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10537MIG. Sirolimus generally arises in the molecular formula C51H79NO13. The term SIROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 8 no. 3 1994, list 34.) SIROLIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule sirolimus under HS 29349990 and SITC 51579. As of Q4 2014, SIROLIMUS remains US FDA's Preferred Term for this commodity. Sirolimus bears US NLM identifiers UMLS ID C0072980 and NCI Concept Code C1212. SMILES: O(C1CC(CCC1O)CC(C1OC(=O)C2N(CCCC2)C(=O)C(=O)C2(OC(CCC2C)CC(OC)C(=CC=CC=CC(CC(C(=O)C(OC)C(O)C(=CC(C(=O)C1)C)C)C)C)C)O)C)C.

